The Cigna Group (CI)
After hours:
| Previous Close | 352.28 |
| Open | 352.56 |
| Bid | 346.68 x 1000 |
| Ask | 354.51 x 1000 |
| Day's Range | 352.36 - 355.86 |
| 52 Week Range | 240.50 - 365.71 |
| Volume | |
| Avg. Volume | 1,544,801 |
| Market Cap | 100.556B |
| Beta (5Y Monthly) | 0.58 |
| PE Ratio (TTM) | 20.37 |
| EPS (TTM) | 17.40 |
| Earnings Date | May 02, 2024 |
| Forward Dividend & Yield | 5.60 (1.59%) |
| Ex-Dividend Date | Mar 05, 2024 |
| 1y Target Est | 383.14 |
Yahoo FinanceWalgreens launches specialty pharmacy unit to compete in new PBM era
Walgreens is launching new services and consolidating specialty services to compete in the pharmacy benefits management (PBM) space.
ReutersCigna to offer Humira rivals with $0 copay at specialty pharmacy
Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June, the health insurer said on Thursday. Cigna said it will stock high- and low-concentration biosimilar versions of Humira from drugmakers including Boehringer Ingelheim, Teva and Alvotech at its Accredo pharmacy.
PR NewswireEvernorth announces Humira biosimilar available at $0 out of pocket for Accredo patients in June
In an important step toward driving long-term affordability and access to treatments for chronic and complex conditions, Evernorth Health Services announced that it will have a Humira® biosimilar available for $0 out of pocket for eligible patients of its specialty pharmacy Accredo beginning this June. The high- and low-concentration interchangeable biosimilar will be produced for Evernorth's affiliate private label pharmaceutical distributor, Quallent Pharmaceuticals, through agreements with mu
